Prosecution Insights
Prosecution Insights
77 pending office actions • 47 clients • 74 examiners • 50 art units • 0 of 77 (0%) have an AI response strategy ready • 88 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 42 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 42 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (1%) |
| §103 only | 36 (47%) |
| §102 only | 6 (8%) |
| §112 only | 7 (9%) |
| Double-patenting only | 9 (12%) |
| Double-patenting + other | 3 (4%) |
| No statute on record | 15 (19%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BREEN, KIMBERLY CATHERINE | 2 | 25.0% | +58.9% |
| KARIMY, TIMOR | 2 | 82.2% | +9.5% |
| BAUSCH, SARAE L | 2 | 29.6% | +44.2% |
| JARRELL, NOBLE E | 1 | 81.1% | +9.3% |
| FERGUSON SAMRETH, MARISSA LIANA | 1 | 69.7% | +11.0% |
| KONVES, ADRIANNA N | 1 | 75.7% | +14.4% |
| OGUNBIYI, OLUWATOSIN A | 1 | 63.5% | +41.8% |
| HIJAZ, OMAR F | 1 | 55.4% | +35.4% |
| EVANS, ASHLEY ELIZABETH | 1 | 13.2% | +34.8% |
| MINCHELLA, ADAM ZACHARY | 1 | 63.8% | +34.1% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17578873 | EMBEDDED TRANSISTOR DEVICES | KARIMY, TIMOR | 2d overdue |
| 19308852 | COMBINATION OF IAP INHIBITORS AND CELLULAR KINASE INHIBITORS, SUCH AS PONATINIB, FOR USE IN THE TREATMENT OF CANCER OR PULMONARY DISEASES, SUCH AS COPD, CYSTIC FIBROSIS, PULMONARY FIBROSIS AND COVID-19 | JARRELL, NOBLE E | — |
| 18390483 | MICRO-TRANSFER PRINTING METHODS | KARIMY, TIMOR | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18490595 | MULTI-MODAL METHODS AND SYSTEMS OF DISEASE DIAGNOSIS | BAUSCH, SARAE L | 11d overdue |
| 19112201 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | BREEN, KIMBERLY CATHERINE | 75d |
| 18835307 | CLASSIFYING TUMORS AND PREDICTING RESPONSIVENESS | EVANS, ASHLEY ELIZABETH | — |
| 18276110 | NUCLEIC ACID AMPLIFICATION USING PROMOTER PRIMERS | BAUSCH, SARAE L | — |
| 17765820 | COMPOSITIONS AND METHODS FOR EXTENDING LIFESPAN | BREEN, KIMBERLY CATHERINE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18935074 | METHODS AND USES OF MICROBIOME COMPOSITIONS | OGUNBIYI, OLUWATOSIN A | 44d overdue |
| 18490595 | MULTI-MODAL METHODS AND SYSTEMS OF DISEASE DIAGNOSIS | BAUSCH, SARAE L | 11d overdue |
| 18728643 | WEARABLES, METHODS, AND SYSTEMS FOR ALERTING USERS TO HEALTH EMERGENCIES | MINCHELLA, ADAM ZACHARY | 22d |
| 19112201 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | BREEN, KIMBERLY CATHERINE | 75d |
| 19283387 | TRANSFER PRINTING STAMPS AND METHODS OF STAMP DELAMINATION | FERGUSON SAMRETH, MARISSA LIANA | — |
| 18989413 | STAMPS FOR MICRO-TRANSFER-PRINTING WITH CURVED STAMP POST ENDS | KONVES, ADRIANNA N | — |
| 18841541 | FOLDABLE PHYSICAL STRUCTURES | HIJAZ, OMAR F | — |
| 18835307 | CLASSIFYING TUMORS AND PREDICTING RESPONSIVENESS | EVANS, ASHLEY ELIZABETH | — |
| Art Unit | Apps |
|---|---|
| 1625 | 4 |
| 1699 | 3 |
| 1657 | 3 |
| 1631 | 3 |
| 1653 | 2 |
| 1645 | 2 |
| 2818 | 2 |
| 1638 | 2 |
| 1626 | 2 |
| 1613 | 2 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19308852 | COMBINATION OF IAP INHIBITORS AND CELLULAR KINASE INHIBITORS, SUCH AS PONATINIB, FOR USE IN THE TREATMENT OF CANCER OR PULMONARY DISEASES, SUCH AS COPD, CYSTIC FIBROSIS, PULMONARY FIBROSIS AND COVID-19 | Tract Pharmaceuticals, Inc. | JARRELL, NOBLE E | 1699 | §112 | Non-Final OA | — | Pending | Aug 25, 2025 |
| 19283387 | TRANSFER PRINTING STAMPS AND METHODS OF STAMP DELAMINATION | X-Celeprint Limited | FERGUSON SAMRETH, MARISSA LIANA | 2853 | §103 | Non-Final OA | — | Pending | Jul 29, 2025 |
| 19112201 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | Marvelbiome, Inc. | BREEN, KIMBERLY CATHERINE | 1653 | DPOther | Non-Final OA | 75d | Pending | Mar 14, 2025 |
| 18989413 | STAMPS FOR MICRO-TRANSFER-PRINTING WITH CURVED STAMP POST ENDS | X-Celeprint Limited | KONVES, ADRIANNA N | §103 | Non-Final OA | — | Pending | Dec 20, 2024 | |
| 18935074 | METHODS AND USES OF MICROBIOME COMPOSITIONS | Marvelbiome, Inc. | OGUNBIYI, OLUWATOSIN A | 1645 | §102 | Non-Final OA | 44d overdue | Pending | Nov 01, 2024 |
| 18841541 | FOLDABLE PHYSICAL STRUCTURES | University Of Maine System Board Of Trustees | HIJAZ, OMAR F | 3635 | §103 | Non-Final OA | — | Pending | Aug 26, 2024 |
| 18835307 | CLASSIFYING TUMORS AND PREDICTING RESPONSIVENESS | Insight Molecular Diagnostics Inc. | EVANS, ASHLEY ELIZABETH | 3687 | §101 | Final Rejection | — | Pending | Aug 01, 2024 |
| 18728643 | WEARABLES, METHODS, AND SYSTEMS FOR ALERTING USERS TO HEALTH EMERGENCIES | Echas LLC | MINCHELLA, ADAM ZACHARY | 3794 | §103 | Non-Final OA | 22d | Pending | Jul 12, 2024 |
| 18770986 | NON-ORTHOGONAL ADDITIVE MANUFACTURING AND THE TREATMENT OF PARTS MANUFACTURED THEREOF | University Of Maine System Board Of Trustees | MORENO HERNANDEZ, JERZI H | 1743 | §112 | Non-Final OA | 8d overdue | Pending | Jul 12, 2024 |
| 18726861 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | Lawrence Livermore National Security, LLC | AGGARWAL, SAHIL CHANDER | DP | Non-Final OA | — | Pending | Jul 05, 2024 | |
| 18718391 | FUSED BENZOISOXAZOLYL COMPOUNDS AS KAT6A INHIBITORS | Olema Pharmaceuticals, Inc. | MOTEVALLI, OROD | DP | Non-Final OA | — | Pending | Jun 10, 2024 | |
| 18654912 | COMPOSITIONS AND METHODS FOR ACCELERATED SOIL STABILIZATION | University Of Maine System Board Of Trustees | GUINO-O UZZLE, MARITES A | §103 | Non-Final OA | — | Pending | May 03, 2024 | |
| 18627691 | SYSTEMS AND METHODS FOR FACILITATING LESION INSPECTION AND ANALYSIS | Exini Diagnostics AB | BEKELE, MEKONEN T | 2699 | §103 | Non-Final OA | 17d overdue | Pending | Apr 05, 2024 |
| 18593039 | TRANSFER-PRINTABLE MICRO-OPTICAL STRUCTURES | X-Celeprint Limited | PENG, CHARLIE YU | 2874 | §103 | Non-Final OA | — | Pending | Mar 01, 2024 |
| 18682205 | ANTI-GDF15 ANTIBODIES, COMPOSITIONS AND USES THEREOF | Adimab, LLC | VAN DRUFF, SYDNEY | DP | Non-Final OA | — | Pending | Feb 08, 2024 | |
| 18390483 | MICRO-TRANSFER PRINTING METHODS | X-Celeprint Limited | KARIMY, TIMOR | 2818 | §103 | Non-Final OA | — | Pending | Dec 20, 2023 |
| 18537611 | METHODS AND COMPOSITIONS FOR TREATING AND MANAGING ALZHEIMER'S DISEASE | Pharmatrophix, Inc. | PARK, HAEJIN S | 1614 | DP | Non-Final OA | — | Pending | Dec 12, 2023 |
| 18537754 | SELECTION BY ESSENTIAL-GENE KNOCK-IN | Editas Medicine, Inc. | HILL, KEVIN KAI | 1638 | §103 | Final Rejection | 30d overdue | Pending | Dec 12, 2023 |
| 18532573 | COMPOUNDS AND COMPOSITIONS AS c-Kit KINASE INHIBITORS | Calixis Inc. | RZECZYCKI, PHILLIP MATTHEW | 1625 | Other | Final Rejection | 35d | Pending | Dec 07, 2023 |
| 18530831 | SYSTEMS AND METHODS FOR PREDICTING BIOCHEMICAL PROGRESSION FREE SURVIVAL IN PROSTATE CANCER PATIENTS | Exini Diagnostics AB | PEHLKE, CAROLYN A | 3799 | §112 | Final Rejection | 18d overdue | Pending | Dec 06, 2023 |
| 18563101 | METHOD OF TREATING ESSENTIAL TREMOR | Cavion, Inc. | FETTEROLF, BRANDON J | 1626 | Other | Non-Final OA | 14d | Pending | Nov 21, 2023 |
| 18561610 | CALIBRATING AN ELECTRONIC CHEMICAL SENSOR TO GENERATE AN EMBEDDING IN AN EMBEDDING SPACE | Osmo Labs, Pbc | COONS, LOGAN DOUGLAS | 2857 | §103 | Non-Final OA | 12d | Pending | Nov 16, 2023 |
| 18560651 | ADENOVIRAL HELPER PLASMID | Forge Biologics, Inc. | BEHARRY, ZANNA MARIA | 1632 | §103 | Non-Final OA | — | Pending | Nov 13, 2023 |
| 18490595 | MULTI-MODAL METHODS AND SYSTEMS OF DISEASE DIAGNOSIS | Universal Diagnostics, S.A. | BAUSCH, SARAE L | 1699 | Other | Non-Final OA | 11d overdue | Pending | Oct 19, 2023 |
| 18381379 | SYSTEMS AND METHODS FOR IN-OPERATING-THEATRE IMAGING OF FRESH TISSUE RESECTED DURING SURGERY FOR PATHOLOGY ASSESSMENT | Samantree Medical (Switzerland) SA | HURST, JONATHAN M | 1799 | §103 | Non-Final OA | 39d | Pending | Oct 18, 2023 |
| 18284959 | COMPOSITIONS AND METHODS FOR INDOOR AIR REMEDIATION | Neoplants SAS | MCWILLIAMS, KELSEY LYNN | 1663 | DP | Non-Final OA | — | Pending | Sep 29, 2023 |
| 18551741 | IMMUNE STIMULATING NANOPARTICLE COMPOSITION | Monta Biosciences Aps | ARNOLD, ERNST V | 1626 | DP | Non-Final OA | — | Pending | Sep 21, 2023 |
| 18244685 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING EYE DISORDERS | Marvelbiome, Inc. | EDWARDS, JESSICA FAYE | 1657 | Other | Non-Final OA | 5d overdue | Pending | Sep 11, 2023 |
| 18452008 | PHARMACEUTICAL PROCESS AND INTERMEDIATES | AstraZeneca AB | OH, TAYLOR V | 1625 | §103 | Non-Final OA | 15d | Pending | Aug 18, 2023 |
| 18277403 | ANTI-PATHOGENIC LIQUID COMPOSITIONS | Claw Biotech Holdings, LLC | KIM, DANIELLE A | 1613 | Other | Non-Final OA | 10d overdue | Pending | Aug 16, 2023 |
| 18276110 | NUCLEIC ACID AMPLIFICATION USING PROMOTER PRIMERS | Sherlock Biosciences, Inc. | BAUSCH, SARAE L | 1699 | §102 | Non-Final OA | — | Pending | Aug 07, 2023 |
| 18274754 | CANCER THERAPY | Surge Therapeutics, Inc. | YANG, TIAN | 1674 | §103 | Non-Final OA | — | Pending | Jul 28, 2023 |
| 18263313 | HHLA2 BINDING AGENTS WITH NOVEL ACTIVITY | NextPoint Therapeutics, Inc. | BERHANE, SELAM | 1675 | §103 | Non-Final OA | — | Pending | Jul 27, 2023 |
| 18219325 | SYSTEMS AND METHODS FOR ARTIFICIAL INTELLIGENCE-BASED PREDICTION OF AMINO ACID SEQUENCES AT A BINDING INTERFACE | Pythia Labs, Inc. | FRUMKIN, JESSE P | 1685 | §102 | Final Rejection | 26d overdue | Pending | Jul 07, 2023 |
| 18260600 | TARGET DETECTION SYSTEMS AND METHODS | Dots Technology Corp. | TURK, NEIL N | 1798 | §103 | Non-Final OA | 42d overdue | Pending | Jul 06, 2023 |
| 18268578 | TAXONOMY-INDEPENDENT CANCER DIAGNOSTICS AND CLASSIFICATION USING MICROBIAL NUCLEIC ACIDS AND SOMATIC MUTATIONS | Universal Diagnostics, S.A. | AUGER, NOAH ANDREW | 1687 | §103 | Non-Final OA | 34d | Pending | Jun 20, 2023 |
| 18019470 | CLASSIFYING TUMORS AND PREDICTING RESPONSIVENESS | Insight Molecular Diagnostics Inc. | DAUNER, JOSEPH G | 1682 | Other | Non-Final OA | 16d | Pending | Jun 16, 2023 |
| 18207246 | SYSTEMS AND METHODS FOR ASSESSING DISEASE BURDEN AND PROGRESSION | Progenics Pharmaceuticals, Inc. | TORRES, JOSE | 2664 | — | Non-Final OA | 169d overdue | Pending | Jun 08, 2023 |
| 18205046 | MONOLITHIC MULTI-FETS | X-Celeprint Limited | HOQUE, MOHAMMAD M | 2817 | §103 | Non-Final OA | — | Pending | Jun 02, 2023 |
| 18142068 | TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS | Olema Pharmaceuticals, Inc. | RODRIGUEZ, RAYNA B | 1628 | DPOther | Non-Final OA | 62d | Pending | May 02, 2023 |
| 18034139 | TRANSDERMAL DELIVERY | Fount Bio, Inc. | BOSWORTH, KAMI A | 3783 | §102 | Final Rejection | 49d overdue | Pending | Apr 27, 2023 |
| 18023909 | MAMMALIAN CELLS AND METHODS FOR ENGINEERING THE SAME | 64-X, Inc. | GROSS, CHRISTOPHER M | 1684 | §112 | Final Rejection | — | Pending | Feb 28, 2023 |
| 18021634 | IMMUNE MODULATION OF MYELOID DERIVED SUPPRESSIVE CELL FUNCTION FOR CANCER TREATMENT | Surge Therapeutics, Inc. | POPA, ILEANA | 1633 | §103 | Final Rejection | 26d overdue | Pending | Feb 16, 2023 |
| 18021076 | RESILIENT BIASED LATCH WITH FUSIBLE RETAINING MEMBER | Sense Biodetection Limited | CHIU, MAY LEUNG | 1758 | §102 | Final Rejection | — | Pending | Feb 13, 2023 |
| 18016096 | PREPARATIONS AND COMPOSITIONS COMPRISING POLYMER COMBINATION PREPARATIONS | Surge Therapeutics, Inc. | WERTZ, ASHLEE ELIZABETH | 1612 | Other | Final Rejection | 4d overdue | Pending | Jan 13, 2023 |
| 18014214 | SYSTEMS AND METHODS FOR ARTIFICIAL INTELLIGENCE-BASED IMAGE ANALYSIS FOR DETECTION AND CHARACTERIZATION OF LESIONS | Exini Diagnostics AB | SANTOS, DANIEL JOSEPH | 2667 | §103 | Final Rejection | — | Pending | Jan 03, 2023 |
| 18012262 | MRNA TRANSFECTION OF IMMUNE CELLS | Carisma Therapeutics Inc. | LEONARD, ARTHUR S | 1631 | Other | Non-Final OA | 15d | Pending | Dec 22, 2022 |
| 18085121 | APPLICATION OF CAS PROTEIN, METHOD FOR DETECTING TARGET NUCLEIC ACID MOLECULE AND KIT | Shanghai Tolo Biotechnology Company Limited | REGA, KYLE THOMAS | 1636 | Other | Non-Final OA | 12d | Pending | Dec 20, 2022 |
| 18001340 | GENETIC MODIFICATION | Peter Biotherapeutics, Inc. | LEITH, NANCY J | 1636 | §103 | Non-Final OA | 26d | Pending | Dec 09, 2022 |
| 18009469 | PHARMACEUTICAL COMPOUND FOR THE TREATMENT OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE | Ferring B.V. | HOWARD, ZACHARY C | 1674 | §103 | Non-Final OA | — | Pending | Dec 09, 2022 |
| 18073511 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING VAGUS NERVE ASSOCIATED DISEASES, DISORDERS, AND CONDITIONS | Marvelbiome, Inc. | REGLAS, GEORGIANA C | 1651 | Other | Non-Final OA | 38d overdue | Pending | Dec 01, 2022 |
| 17982866 | SYSTEMS AND METHODS FOR REAL-TIME MEASUREMENT AND CONTROL OF SPRAYED LIQUID COVERAGE ON PLANT SURFACES | Agzen Inc. | ERDMAN, CHAD G | 2116 | §103 | Non-Final OA | 57d | Pending | Nov 08, 2022 |
| 17923293 | METHODS AND DEVICES FOR TREATMENT OF NEUROPATHY | University Of Maine System Board Of Trustees | PRICE, NATHAN R | 3783 | §103 | Final Rejection | — | Pending | Nov 04, 2022 |
| 17980755 | SYSTEMS AND METHODS FOR PREPARING BIOLOGICAL SAMPLES FOR GENETIC SEQUENCING | Universal Diagnostics, S.A. | PHAM, KHAI QUYNH TIEN | 1684 | §103 | Final Rejection | 9d | Pending | Nov 04, 2022 |
| 17920385 | COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF VIRAL INFECTIONS | Ned Biosystems, Inc. | WHITE, DAWANNA SHAR-DAY | 1627 | DPOther | Final Rejection | — | Pending | Oct 20, 2022 |
| 17761594 | COMPOSITIONS AND METHODS FOR MICROBIOME MODULATION | Washington University | SINGH, SATYENDRA K | 1657 | §103 | Final Rejection | — | Pending | Oct 11, 2022 |
| 17914933 | METHODS FOR PRECISE AND BIAS-FREE QUANTIFICATION OF CELL-FREE DNA | Chronix Biomedical | WILDER, CYNTHIA B | 1681 | §102 | Final Rejection | — | Pending | Sep 27, 2022 |
| 17909315 | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | Aleta Biotherapeutics Inc. | O'BRIEN, LEA S | 1646 | §103 | Final Rejection | — | Pending | Sep 02, 2022 |
| 17897878 | LIPID NANOPARTICLE FORMULATIONS FOR CRISPR/CAS COMPONENTS | Intellia Therapeutics, Inc. | NGUYEN, QUANG | 1631 | Other | Final Rejection | 238d overdue | Pending | Aug 29, 2022 |
| 17791785 | COMPOSITIONS AND METHODS FOR TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) AND OTHER NEURODEGENERATIVE DISEASES | The Sallie Astor Burdine Breast Foundation | BENZION, GARY | 1681 | §103 | Non-Final OA | 15d | Pending | Jul 08, 2022 |
| 17808868 | TEAD INHIBITORS AND USES THEREOF | Cedilla Therapeutics, Inc. | SEAMAN, D MARGARET M | 1625 | §112 | Non-Final OA | — | Pending | Jun 24, 2022 |
| 17786753 | ENGINEERED CELLS FOR THERAPY | Editas Medicine, Inc. | GONZALES, JOSEPHINE MARIA | 1631 | §103 | Non-Final OA | 66d overdue | Pending | Jun 17, 2022 |
| 17842762 | FGF-18 IN GRAFT TRANSPLANTATION AND TISSUE ENGINEERING PROCEDURES | Merck Patent GmbH | MOSS, NATALIE M | 1653 | §103 | Non-Final OA | 12d | Pending | Jun 16, 2022 |
| 17744231 | METHODS FOR DISEASE DETECTION | Universal Diagnostics, S.A. | CASH, KAILEY ELIZABETH | 1683 | §103 | Non-Final OA | 29d | Pending | May 13, 2022 |
| 17772863 | LIGNOCELLULOSIC FOAM COMPOSITIONS AND METHODS OF MAKING THEREOF | University Of Maine System Board Of Trustees | DONAHUE, OLGA LUCIA | 1763 | §103 | Non-Final OA | 22d | Pending | Apr 28, 2022 |
| 17765820 | COMPOSITIONS AND METHODS FOR EXTENDING LIFESPAN | Marvelbiome, Inc. | BREEN, KIMBERLY CATHERINE | 1657 | Other | Final Rejection | — | Pending | Mar 31, 2022 |
| 17706028 | ANTI CD25 FC GAMMA RECEPTOR BISPECIFIC ANTIBODIES FOR TUMOR SPECIFIC CELL DEPLETION | Cancer Research Technology Limited | OUSPENSKI, ILIA I | 1644 | Other | Final Rejection | 57d | Pending | Mar 28, 2022 |
| 17696509 | TRANSDERMAL DELIVERY OF LARGE AGENTS | Eirion Therapeutics, Inc. | SHIN, MONICA A | 1616 | §103 | Final Rejection | 147d overdue | Pending | Mar 16, 2022 |
| 17578873 | EMBEDDED TRANSISTOR DEVICES | X-Celeprint Limited | KARIMY, TIMOR | 2818 | §103 | Non-Final OA | 2d overdue | Pending | Jan 19, 2022 |
| 17503056 | DETECTION AND QUANTIFICATION OF DONOR CELL-FREE DNA IN THE CIRCULATION OF ORGAN TRANSPLANT RECIPIENTS | Chronix Biomedical | KAPUSHOC, STEPHEN THOMAS | 1683 | Other | Final Rejection | 107d overdue | Pending | Oct 15, 2021 |
| 17428995 | TREATMENT OF PATIENTS AT RISK OF RAPID PROGRESSION OF OSTEOARTHRITIS WITH AN FGF-18 COMPOUND | Merck Patent GmbH | SAOUD, CHRISTINE J | 1645 | §103 | Non-Final OA | 23d | Pending | Aug 06, 2021 |
| 17366830 | CANCER THERAPY | Ned Biosystems, Inc. | TRAN, ERIC | 1629 | §112 | Non-Final OA | — | Pending | Jul 02, 2021 |
| 17297493 | IMPROVED DELIVERY OF LARGE AGENTS | Eirion Therapeutics, Inc. | FUBARA, BLESSING M | 1613 | DP | Non-Final OA | — | Pending | May 27, 2021 |
| 17274948 | PLASMINOGEN ACTIVATOR INHIBITOR 1 (PAI-1) INHIBITORS AND USES THEREFOR | Eirion Therapeutics, Inc. | MCANANY, JOHN D | 1625 | DP | Non-Final OA | — | Pending | Mar 10, 2021 |
| 17251447 | REVERSED UNIVERSAL CHIMERIC ANTIGEN RECEPTOR EXPRESSING IMMUNE CELLS FOR TARGETING OF DIVERSE MULTIPLE ANTIGENS AND METHOD OF MANUFACTURING THE SAME AND USE OF THE SAME FOR TREATMENT OF CANCER, INFECTIONS AND AUTOIMMUNE DISORDERS | AvenCell Europe GmbH | COOK, LISA V | 1642 | DP | Non-Final OA | — | Pending | Dec 11, 2020 |
| 16651911 | FORMULATIONS | Intellia Therapeutics, Inc. | BURKHART, MICHAEL D | 1638 | §103 | Final Rejection | — | Pending | Mar 27, 2020 |
| 16284963 | PROSTATE CANCER ASSOCIATED CIRCULATING NUCLEIC ACID BIOMARKERS | Chronix Biomedical | SITTON, JEHANNE SOUAYA | 1682 | §112 | Non-Final OA | 44d overdue | Pending | Feb 25, 2019 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial